menu
    • menu
    [{"orgOrder":0,"company":"BIOTON S.A","sponsor":"BIOTON S.A","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor","graph1":"Neurology","graph2":"Phase I","graph3":"BIOTON S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"BIOTON S.A \/ BioPartners","highestDevelopmentStatusID":"6","companyTruncated":"BIOTON S.A \/ BioPartners"},{"orgOrder":0,"company":"BIOTON S.A","sponsor":"BIOTON S.A","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Interferon Beta-1A","moa":"Interferon alpha\/beta receptor","graph1":"Neurology","graph2":"Phase I","graph3":"BIOTON S.A","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"BIOTON S.A \/ BioPartners","highestDevelopmentStatusID":"6","companyTruncated":"BIOTON S.A \/ BioPartners"}]

    Find Clinical Drug Pipeline Developments & Deals by BIOTON S.A

    Menu

    BIOTON S.A

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BIOTON S.A

                            Poland arrow
                            BOS Manchester
                            Not Confirmed

                            BIOTON S.A

                            Poland arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interferon Beta-1A

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Recipient : Centre Hospitalier Universitaire Vaudois

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase I BP Interferon (IFN) Beta-004

                            Details : Interferon Beta-1a is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Multiple Sclerosis, Relapsing-Remitting.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 07, 2015

                            Lead Product(s) : Interferon Beta-1A

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Recipient : Centre Hospitalier Universitaire Vaudois

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BIOTON S.A

                            Poland arrow
                            BOS Manchester
                            Not Confirmed

                            BIOTON S.A

                            Poland arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Interferon Beta-1A

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Recipient : Centre Hospitalier Universitaire Vaudois

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase I BP Interferon (IFN) Beta-001

                            Details : Interferon Beta-1a is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Multiple Sclerosis, Relapsing-Remitting.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 05, 2015

                            Lead Product(s) : Interferon Beta-1A

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Recipient : Centre Hospitalier Universitaire Vaudois

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth